Results 81 to 90 of about 1,261,208 (309)

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer

Frontiers in Nutrition, 2023
BackgroundThe purpose of this study was to investigate the prognostic significance of sarcopenia diagnosed based on anthropometric equations for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC).MethodsA ...
Hailun Xie, Hailun Xie, Lishuang Wei, Shunhui Gao, Shunhui Gao, Mingxiang Liu, Mingxiang Liu, Yanren Liang, Yanren Liang, Guanghui Yuan, Guanghui Yuan, Qiwen Wang, Qiwen Wang, Yansong Xu, Shuangyi Tang, Jialiang Gan, Jialiang Gan   +16 more
doaj   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas

Endocrine Oncology
Objective: Glucagonomas are rare islet cell tumours, accounting for 2% of such tumours, with an annual incidence of 0.01–0.1 per million. This study aimed to describe diagnostic characteristics and treatment outcomes in patients with glucagonoma from a ...
Eleni Armeni, Alexander Branton, Juliana Porto, Dalvinder Mandair, Aimee R Hayes, Aspasia Manta, Shaunak Navalkissoor, Gopinath Gnanasegaran, Ann-Marie Quigley, Ashley B Grossman, Martyn Caplin, Christos Toumpanakis   +11 more
doaj   +1 more source

PF389 PROGRESSION‐FREE SURVIVAL PREDICTS OVERALL SURVIVAL IN FRONTLINE CLL

HemaSphere, 2019
Background:Many phase II and III trials in oncology utilise the surrogate endpoint progression‐free survival (PFS) as the primary endpoint; however, the relationship between a surrogate endpoint and true clinical benefit in terms of overall survival (OS) or quality of life must be demonstrated.Aims:This research aimed to explore and quantify the ...
S. Baculea, S. Horsburgh, S. Chadda, L. Nelson, C. LeReun   +4 more
openaire   +1 more source

Prognostic Factors of Atypical Meningioma : Overall Survival Rate and Progression Free Survival Rate [PDF]

Journal of Korean Neurosurgical Society, 2017
Atypical meningioma is rare tumor and there is no accurate guide line for optimal treatment. This retrospective study analyzed the prognostic factors, the effect of different methods of treatments and the behavior of atypical meningioma.Thirty six patients were diagnosed as atypical meningioma, among 273 patients who were given a diagnosis of ...
Lee, Jae Ho, Kim, Oh Lyong, Seo, Young Beom, Choi, Jun Hyuk   +3 more
openaire   +2 more sources

The newfound relationship between extrachromosomal DNAs and excised signal circles

FEBS Letters, EarlyView.
Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley   +1 more source

Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands

Health and Quality of Life Outcomes, 2012
Background Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR).
Verduyn S, Biesma Bonne, Schramel Franz MNH, van der Scheer Feike W, Langenfeld Merel K, de Peuter Maria A, Dingemans Anne-Marie C   +6 more
doaj   +1 more source

BEV-IP : perioperative chemotherapy with bevacizumab in patients undergoing cytoreduction and intraperitoneal chemoperfusion for colorectal carcinomatosis [PDF]

, 2015
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC).
Ceelen, Wim, Liberale, Gabriel, Van Der Speeten, Kurt, Willaert, Wouter   +3 more
core   +2 more sources